MediWound Ltd.

How big is MediWound Ltd.?

As of Jun 18, MediWound Ltd. has a market capitalization of 213.78 million, with net sales of 19.22 million and a net profit of -21.23 million over the latest four quarters. Shareholder's funds are 31.15 million, and total assets are 73.50 million.

As of Jun 18, MediWound Ltd. has a market capitalization of 213.78 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 19.22 million, while the sum of Net Profit for the same period is -21.23 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 31.15 million and Total Assets at 73.50 million.

What does MediWound Ltd. do?

MediWound Ltd. is an Israeli biopharmaceutical company focused on developing and commercializing products for severe burns, chronic wounds, and connective tissue disorders. As of March 2025, it reported net sales of $4 million and a net loss of $1 million, with a market cap of $213.78 million.

Overview: <BR>MediWound Ltd. is an Israel-based biopharmaceutical company that develops, manufactures, and commercializes therapeutic products in the fields of severe burns, chronic and other hard-to-heal wounds, and connective tissue disorders, operating within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 4 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -1 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 213.78 Million (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.20 <BR>Return on Equity: -67.86% <BR>Price to Book: 6.84 <BR><BR>Contact Details: <BR>Address: 42 Hayarkon Street, YAVNE None: 8122745 <BR>Tel: 972 8 9324010 <BR>Fax: 972 8 9324011 <BR>Website: http://www.mediwound.com

Who are in the management team of MediWound Ltd.?

As of March 2022, the management team of MediWound Ltd. includes Mr. Stephen Wills (Executive Chairman), Mr. David Fox, Mr. Ofer Gonen, Mr. Samuel Moed, Mr. Assaf Segal (all Directors), and Dr. Vickie Driver (Independent Director). They oversee the company's strategic direction and operations.

As of March 2022, the management team of MediWound Ltd. includes the following individuals:<BR><BR>- Mr. Stephen Wills, Executive Chairman of the Board<BR>- Mr. David Fox, Director<BR>- Mr. Ofer Gonen, Director<BR>- Mr. Samuel Moed, Director<BR>- Mr. Assaf Segal, Director<BR>- Dr. Vickie Driver, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

Should I buy, sell or hold MediWound Ltd.?

Is MediWound Ltd. overvalued or undervalued?

As of August 6, 2020, MediWound Ltd. is considered overvalued and risky due to poor financial metrics, including a high Price to Book Value of 7.46 and negative EV to EBIT and EV to EBITDA ratios, indicating significant struggles compared to its peers.

As of 6 August 2020, the valuation grade for MediWound Ltd. changed from attractive to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued given its significant negative financial metrics, including a Price to Book Value of 7.46, an EV to EBIT of -9.39, and an EV to EBITDA of -10.10. These ratios suggest that the company's valuation does not align with its current financial performance.<BR><BR>In comparison to its peers, MediWound Ltd. has a worse EV to EBITDA ratio than Esperion Therapeutics, Inc. at -28.9150 and a higher Price to Book Value than Oramed Pharmaceuticals, Inc. at 0.2489. The negative ROE of -67.86% further underscores the company's struggles relative to its industry. While recent stock performance data is not available for a direct comparison with the S&P 500, the overall financial indicators suggest that MediWound Ltd. is currently overvalued.

Is MediWound Ltd. technically bullish or bearish?

As of September 12, 2025, MediWound Ltd. shows a mildly bearish trend with bearish weekly and monthly MACD and KST indicators, underperforming the S&P 500 year-to-date and over the past year.

As of 12 September 2025, the technical trend for MediWound Ltd. has changed from mildly bullish to mildly bearish. The weekly MACD and KST indicators are bearish, while the monthly MACD and KST are mildly bearish. The daily moving averages indicate a mildly bullish stance, but overall, the weekly Bollinger Bands are bearish, and the monthly Bollinger Bands are sideways. The Dow Theory shows a mildly bearish trend on the monthly timeframe. <BR><BR>In terms of performance, MediWound has underperformed the S&P 500 across multiple periods, with a year-to-date return of -3.09% compared to the S&P 500's 12.22%, and a one-year return of -1.82% versus 17.14%. Overall, the current technical stance is mildly bearish.